pharmaceutical-investing Ironwood and Alnylam Enter US GI Disease Education and Promotional Agreement
pharmaceutical-investing Approval of Linzess Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation
pharmaceutical-investing Ironwood Pharmaceuticals Initiates Phase IIIb Study of Linaclotide in Adult Patients with Irritable Bowel Syndrome with Constipation (IBS-C
Ironwood Pharmaceuticals Announces FDA Orphan Drug Designation for Olinciguat for the Treatment of Sickle Cell Disease
